TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.

Chung-Han Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.